Brief: Egetis Therapeutics H1 Adjusted EPS SEK -0.5
22/08/2024 06:00
Aug 22 (Reuters) - Egetis Therapeutics H1 revenue SEK 25.9 million. * H1 net income SEK -146.9 million
Recent news on Egetis Therapeutics AB (publ)
See all newsBrief: Egetis Announces Grant Of Patent For MCT8 Deficiency Composition In U.S.
Swedisg drugmaker Egetis's Q1 revenue rises 9% on Emcitate sales in Europe
Brief: Egetis Therapeutics Q1 Loss SEK 94.5 Mln
Brief: Egetis Plans Directed Share Issue Raising SEK 350 Million
Brief: Egetis Therapeutics Appoints Tiago Nunes As CMO Effective May 1